Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 411,600 shares, a growth of 5,697.2% from the October 31st total of 7,100 shares. Approximately 11.3% of the shares of the company are sold short. Based on an average daily volume of 420,600 shares, the short-interest ratio is currently 1.0 days.
Pulmatrix Stock Up 16.7 %
PULM stock opened at $7.34 on Thursday. The business’s 50-day moving average price is $2.82 and its 200-day moving average price is $2.30. The stock has a market cap of $26.79 million, a P/E ratio of -2.81 and a beta of 0.99. Pulmatrix has a twelve month low of $1.55 and a twelve month high of $8.44.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on Pulmatrix in a research report on Tuesday. They set a “hold” rating on the stock.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Read More
- Five stocks we like better than Pulmatrix
- What Is WallStreetBets and What Stocks Are They Targeting?
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- Consumer Discretionary Stocks Explained
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
